CorMedix Inc. Q3 2025 Earnings Recap

CRMD Q3 2025 November 12, 2025

Get alerts when CRMD reports next quarter

CorMedix delivered its strongest financial quarter to date, bolstered by the transformational acquisition of Melinta Therapeutics, driving record revenue and substantial EBITDA growth.

Earnings Per Share Beat

$0.57 vs $0.48 est.

+18.7% surprise

Revenue Miss

104275289 vs 127022710 est.

-17.9% surprise

Market Reaction

1-Day +2.06%

5-Day -10.81%

30-Day -5.63%

See CRMD alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved record revenue of $104.3 million and net income of $108.6 million, significantly enhancing financial performance.
Raised full year revenue guidance from $375 million to a range of $390 million to $410 million, reflecting strong market momentum.
Announced a strategic minority investment in Talphera Inc., positioning CorMedix for expansion into critical care.
Integration of Melinta operations ahead of schedule, with expected synergies of $30 million from a total of $35-$45 million by late 2025.
Upcoming catalysts include pivotal Phase III data for Rezzayo in invasive fungal infection prophylaxis and expansion of DefenCath to prevent CLABSI in TPN patients.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CRMD on AllInvestView.

Next Q1 2026